Domain antibody construct
The present invention provides a domain antibody construct which binds to human TNF-α, with the construct comprising: (a) a domain antibody (dAb) which binds to human TNF-α; (b) a modified hinge region sequence; (c) a human or primate heavy chain constant region sequence having a truncated C H 1 domain of not more than 20 residues, wherein the modified hinge region sequence contains either a deletion or a single amino acid substitution of at least one cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.
1. A domain antibody construct which binds to human TNF-α, wherein the amino acid sequence of the domain antibody construct is identical to the sequence set forth in SEQ ID No:11.
2. A dimeric domain antibody construct which binds to human TNF-α, wherein the dimeric domain antibody construct consists of two domain antibody constructs according to claim 1 and which is homodimer.
3. A pharmaceutical composition comprising a therapeutically effective amount of a domain antibody construct according to claim 1 , together with a pharmaceutically acceptable carrier or diluent.
4. A pharmaceutical composition comprising a therapeutically effective amount of a dimeric domain antibody construct according to claim 2 , together with a pharmaceutically acceptable carrier or diluent.